Kura Oncology (KURA) Looks Good: Stock Adds 6.8% in Session
Kura Oncology, Inc. KURA was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company — as the stock is now up 28.5% in the past one-month time frame.
The company has seen three positive estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for Kura Oncology. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Kura Oncology currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.
Kura Oncology, Inc. Price
A better-ranked stock in the Medical sector is AVEO Pharmaceuticals Inc AVEO, which currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks’ Single Best Pick to Double
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
With users in 180 countries and soaring revenues, it’s set to thrive on remote working long after the pandemic ends. No wonder it recently offered a stunning $600 million stock buy-back plan.
The sky’s the limit for this emerging tech giant. And the earlier you get in, the greater your potential gain.
Click to get this free report
AVEO Pharmaceuticals, Inc. (AVEO): Free Stock Analysis Report
Kura Oncology, Inc. (KURA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.